[DOI] [PMC free article] [PubMed] [Google Scholar] 100.Wong C.C.Y., Smith R.G., Hannon E., Ramaswami G., Parikshak N.N., Assary E., Troakes C., Poschmann J., Schalkwyk L.C., Sun W., et al
The analysis was conducted in the modified intent-to-treat (mITT) analysis set [all treated subjects with onset of symptoms 3 days who at baseline did not receive nor were expected to receive COVID-19 therapeutic monoclonal antibody (mAb) treatment], the mITT1 analysis set (all treated subjects with onset of symptoms 5 days who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment), and the mITT2 analysis set (all treated subjects with onset of symptoms 5 days)
Targeting SLC1A5 and SLC3A2/SLC7A5 as a potential strategy to strengthen anti-tumor immunity in the tumor microenvironment
Reduced oxidative stress: Lowers the risk of chronic diseases